Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

    SAN DIEGO, March 11 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX:
NVN) today announced that the Company has completed enrollment and initiated
dosing of the fourth and final cohort of patients in its Phase 1 dose
escalation trial.  This study examines the safety of its lead candidate, new
HspE7 (HspE7 + Poly-ICLC, a toll-like receptor-3, or TLR3 agonist), in
patients with cervical intraepithelial neoplasia, or CIN, a precursor to
cervical cancer.  New HspE7 is an investigational therapeutic vaccine
targeting human papillomavirus (HPV)-related diseases.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)
    "Conclusion of enrollment in this study is a significant milestone for
Nventa," said Gregory M. McKee, President and Chief Executive Officer at
Nventa.  "We have spent considerable time analyzing the need for a fifth
cohort in this study, and have determined that the fourth cohort dose level is
likely optimal for future clinical trials.  Following completion of this Phase
1 study, we anticipate launching a comprehensive Phase 2 program studying the
safety and efficacy of new HspE7 in patients with CIN."
    When complete, the Phase 1 trial will have dosed four cohorts totaling
seventeen patients with a fixed dose of 500 mcg of HspE7 and either 50, 500,
1,000 or 2,000 mcg of the adjuvant, Poly-ICLC.  In addition to safety data,
immunological data are being collected pre-treatment, following each dose of
new HspE7, and at the end of the study from all patients, which could provide
an early indication of potential activity of new HspE7.  All patients are also
being typed for class I and II human leukocyte antigen (HLA) subtypes, and are
being evaluated for cytokine responses, anti-HspE7 antibodies and cellular
(T-cell) immunology.
    Affiliations and investigators in this trial currently have included the
Montefiore Medical Center; William D. Kolton, M.D. of San Diego, California;
Linda Roman, M.D. of the University of Southern California (USC); Michael L.
Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T.
Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research
in Pleasant Grove, Utah.
    About New HspE7:
    The Company's lead candidate, new HspE7 (HspE7 + Poly-ICLC), is a novel
therapeutic candidate intended for the treatment of precancerous and cancerous
lesions caused by the human papillomavirus (HPV), one of the most common
sexually transmitted diseases in the world.  New HspE7 contains the novel
CoVal(TM) fusion protein, HspE7 co-administered with the adjuvant, Poly-ICLC,
a toll-like receptor-3 (TLR3) agonist adjuvant.  An adjuvant is a substance
added to vaccines to improve immune responses against target antigens.  HspE7
is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses
recombinant DNA technology to covalently fuse stress proteins to target
antigens, thereby stimulating cellular immune system responses.  Nventa is
developing new HspE7 for multiple indications.
    About Nventa Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV).  The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.  For more information about Nventa, please
visit http://www.nventacorp.com.
    This press release contains statements which may constitute
forward-looking information under applicable Canadian securities legislation
or forward-looking statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995.  Such forward-looking statements or
information may include financial and other projections as well as statements
regarding the Company's future plans, objectives, performance, revenues,
growth, profits, operating expenses or the Company's underlying assumptions.
The words "may", "would", "could", "will", "likely", "expect", "anticipate",
"intend", "plan", "forecast", "project", "estimate" and "believe" or other
similar words and phrases may identify forward-looking statements or
information.  Persons reading this press release are cautioned that such
statements or information are only predictions, and that the Company's actual
future results or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning: the optimal dose
level for future clinical trials; completion of the Phase 1 trial; the
launching of a comprehensive Phase 2 program in patients with CIN; the number
of cohorts and patients and the expected dosing amounts in the Phase 1 trial;
and the collection and use of immunological data to indicate potential
activity of new HspE7.
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments to be materially different from results, events or
developments expressed or implied by such forward-looking statements or
information. Such factors include, among others, our need for capital; the
outcomes of our clinical trials; risks associated with requirements for
approvals by government agencies such as the FDA before products can be tested
in clinical trials; the possibility that such government agency approvals will
not be obtained in a timely manner or at all or will be conditioned in a
manner that would impair our ability to advance development; risks associated
with the requirement that a drug be found safe and effective after extensive
clinical trials; our dependence on suppliers, collaborative partners and other
third parties and the prospects and timing for negotiating supply agreements,
corporate collaborations or licensing arrangements; our ability to attract and
retain key personnel; and other factors as described in detail in our filings
with the Canadian securities regulatory authorities at http://www.sedar.com.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that we will raise enough capital, on reasonable terms and in a timely
manner; that we will retain our key personnel; that we will obtain the
necessary regulatory approvals related to HspE7 and our adjuvant in a timely
manner; that enough HspE7 will be available to conduct our planned trials;
that we will be able to procure the necessary amount of adjuvant to conduct
our planned trials; that we will obtain timely approval from additional IRBs;
that the results from additional preclinical and clinical work, if any, will
be consistent with the results we have already obtained; that a sufficient
number of patients will be available to conduct our planned trials; and that
sufficient data will be generated to support our IND.
    In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we may
not be able to continue in our business as planned.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2006 Annual
Information Form filed on SEDAR at http://www.sedar.com.  Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization, including Old Stressgen's 2005 Annual
Information Form dated March 16, 2006 may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Communications Corp.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

For further information:

For further information: Donna Slade, Director, Investor Relations, 
+1-858-202-4945, dslade@nventacorp.com Web Site: http://www.nventacorp.com/

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890